# Ponatinib in Advanced NSCLC w/ RET Translocations

> **NCT01813734** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 9 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Ponatinib

## Key facts

- **NCT ID:** NCT01813734
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2018-06
- **Final completion:** 2018-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01813734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01813734, "Ponatinib in Advanced NSCLC w/ RET Translocations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01813734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*